Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a decline in financing net purchases and a decrease in revenue and net profit for the first nine months of 2025 [1][2] Group 2 - On November 25, He Yuan Bio's stock rose by 0.99%, with a trading volume of 361 million yuan [1] - The financing data on November 25 showed a financing purchase amount of 34.16 million yuan and a financing repayment of 64.34 million yuan, resulting in a net financing purchase of -30.18 million yuan [1] - As of November 25, the total balance of margin trading for He Yuan Bio was 313 million yuan, accounting for 9.87% of its circulating market value [1] Group 3 - As of October 28, the number of shareholders for He Yuan Bio was 47,100, an increase of 84,075% compared to the previous period [2] - The average circulating shares per person decreased to 869 shares, a reduction of 99.85% from the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.66 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, a year-on-year decrease of 8.44% [2]
禾元生物11月25日获融资买入3415.52万元，融资余额3.13亿元